Gene therapy in hemiparkinsonian rhesus monkeys: Long-term survival and behavioral recovery by transplantation of autologous human tyrosine hydroxylase-expressing neural stem cells

Cytotherapy

Volumn 12, Issue 2, 2010, Pages 226-237

  Xu, Qiang ^a,b,c   Jiang, Xiaodan ^a,b   Ke, Yiquan ^a,b   Zhang, Shizhong ^a,b   Xu, Ruxiang ^a,b,c   Zeng, Yanjun ^d  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d BEIJING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Gene therapy; Neural stem cells; Parkinson's disease; Rhesus monkey; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; NEUROTRANSMITTER; NORADRENALIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BONE MARROW; CAUDATE NUCLEUS; CELL ISOLATION; CELL SURVIVAL; CELL TRANSPLANTATION; CONTROLLED STUDY; DOPAMINE METABOLISM; GENE EXPRESSION; GENE THERAPY; GLUCOSE METABOLISM; HEMIPARKINSONIAN RHESUS MONKEY; IN VITRO STUDY; MALE; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; STROMA CELL; SUBSTANTIA NIGRA; SURVIVAL TIME;

EID: 77749298356     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653240903490371     Document Type: Article

References (44)

1. Mendez I, Sanchez-Pernaute R, Cooper O, et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain. 2005;128:1498-510.
2. Freed CR, Breeze RE, Rosenberg NL, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med. 1992;327:1549-55.
3. Widner H, Tetrud J, Rehncrona S, Snow B, et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med. 1992;327:1556-63.
4. Fisher LJ, Jinnah HA, Kale LC, et al. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa. Neuron. 1991;6:371-80.
5. Horellou P, Mallet J. Gene therapy for Parkinson's disease. Mol Neurobiol. 1997;15:241-56.
6. During MJ, Samulski RJ, Elsworth JD, et al. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther. 1998;5:820-7.
7. Diduch DR, Coe MR, Joyner C, et al. Two cell lines from bone marrow that differ in terms of collagen synthesis, osteogenic characteristics, and matrix mineralization. J Bone Joint Surg Am. 1993;75:92-105.
8. Caplan AI. Mesenchymal stem cells and gene therapy. Clin Orthop Relat Res. 2000;379 (Suppl):S67-70.
9. Bruder SP, Jaiswal N, Haynesworth SE. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem. 1997; 64:278-94.
10. Prockop DJ, Sekiya I, Colter DC. Isolation and characterization of rapidly self-renewing stem cells from cultures of human marrow stromal cells. Cytotherapy. 2001;3:393-6.
11. Eglitis MA, Mezey E. Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci USA. 1997;94:4080-5.
12. Pereira RF, O'Hara MD, Laptev AV, et al. Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci USA. 1998;95:1142-7.
13. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci USA. 1999;96:10711-16.
14. Levy YS, Bahat-Stroomza M, Barzilay R, et al. Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease. Cytotherapy. 2008; 10:340-52.
15. Schwarz EJ, Reger RL, Alexander GM, et al. Rat marrow stromal cells rapidly transduced with a self-inactivating retrovirus synthesize L-DOPA in vitro. Gene Ther. 2001;8: 1214-23
16. Jiang X, Xu R, Yang Z, Jin P, Xu Q. Experimental study on trace marking and oncogenicity of neural stem cells derived from bone marrow. Cell Mol Neurobiol. 2008;28:689-711.
17. Pitts SM, Markey SP, Murphy DL, et al. Recommended practices for the safe handling of MPTP. In: Markey SP, Castagnoli N, Trevor AJ, Kopin IJ. MPTP: A neurotoxin producing a Parkinsonian syndrome. Orlando: Academic Press; 1986. p. 703-15.
18. Elsworth JD, Deutch AY, Redmond DE Jr, et al. Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine-treated primates: biochemical changes in striatal regions. Neuroscience. 1989;33:323-31.
19. Ovadia A, Zhang Z, Gash DM. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol Aging. 1995;6:931-937.
20. Smeyne RJ, Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res Mol Brain Res. 2005;134:57-66.
21. O'Malley KL, Anhalt MJ, Martin BM, et al. Isolation and characterization of the human tyrosine hydroxylase gene: identification of 5′ alternative splice sites responsible for multiple mRNAs. Biochemistry. 1987;26:6910-14.
22. Jiang X, Xu R, Guo Z, et al. Neurobiochemistry and neuroelectrophysiology of neuron-like cells differentiated from neural BMSCs-D-NSCs. Conf Proc IEEE Eng Med Biol Soc. 2005;5:5215-18.
23. Collier TJ, Sortwell CE, Elsworth JD, et al. Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple-target grafting as a therapy for Parkinson's disease. J Comp Neurol. 2002;442:320-30.
24. Bjugstad KB, Redmond DE Jr, Teng YD, et al. Neural stem cells implanted into MPTP-treated monkeys increase the size of endogenous tyrosine hydroxylase-positive cells found in the striatum: a return to control measures. Cell Transplant. 2005;14:183-92.
25. Ostenfeld T, Svendsen CN. Recent advances in stem cell neurobiology. Adv Tech Stand Neurosurg. 2003;28:3-89.
26. Lakatos A, Franklin RJ. Transplant mediated repair of the central nervous system: an imminent solution? Curr Opin Neurol. 2002;15:701-5.
27. Riess P, Zhang C, Saatman KE, et al. Transplanted neural stem cells survive, differentiate, and improve neurological motor function after experimental traumatic brain injury. Neurosurgery. 2002;51:1043-54.
28. Beyer Nardi N, da Silva Meirelles L. Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb Exp Pharmacol. 2006;174:249-82.
29. Woodbury D, Schwarz EJ, Prochop DJ, et al. Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res. 2000;61:364-70.
30. Hermann A, Gastl R, Liebau S, et al. Efficient generation of neural stem cell-like cells from adult human bone marrow stromal cells. J Cell Sci. 2004;117:4411-22.
31. Katarzyna A, Kuzhikandathil EV, Rameshwar P, Trzaska KA, Eldo V, et al. Specification of a dopaminergic phenotype from adult human mesenchymal stem cells. Stem Cell. 2007;25:2797-808.
32. Garcia AD, Doan NB, Imura T, et al. GFAP-expressing progenitors are the principal source of constitutive neurogenesis in adult mouse forebrain. Nat Neurosci. 2004;7:1233-41.
33. Bonaguidi MA, McGuire T, Hu M, et al. LIF and BMP signaling generate separate and discrete types of GFAP-expressing cells. Development. 2005;132:5503-14.
34. Coyne TM, Akiva J, Marcus AJ, Woodbury D, Black IB, et al. Marrow stromal cells transplanted to the adult brain are rejected by an inflammatory response and transfer donor labels to host neurons and glia. Stem Cells. 2006;24:2483-92.
35. Fischman AJ, Babich JW, Elmaleh DR, et al. SPECT imaging of dopamine transporter sites in normal and MPTP-treated rhesus monkeys. J Nucl Med. 1997;38:144-50.
36. 18F-FDOPA PET in Parkinson's disease patients. J Nucl Med. 2003;44:999-1005.
37. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in striatum of patients with idiopathic Parkinson's disease. N Engl J Med. 1988;876:876-80
38. Chen Y, Teng F, Tang B. Coaxing bone marrow stromal mesenchymal stem cells towards neuronal differentiation: progress and uncertainties. Cell Mol Life Sci. 2006;63: 1649-57.
39. Pisati F, Bossolasco P, Meregalli M, et al. Induction of neurotrophin expression via human adult mesenchymal stem cells: implication for cell therapy in neurodegenerative diseases. Cell Transplant. 2007;16:41-55.
40. Le Blanc K, Ringden O. Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr Opin Immunol. 2006;18:586-91.
41. Deng YB, Liu XG, Liu ZG, et al. Implantation of BM mesenchymal stem cells into injured spinal cord elicits de novo neurogenesis and functional recovery: evidence from a study in rhesus monkeys. Cytotherapy. 2006;8:210-14.
42. Berding G, Odin P, Brooks DJ, et al. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with F-18 FDG-PET. Mov Disord. 2001;16:1014-22.
43. Eidelberg D, Moeller JR, Ishikawa T, et al. Early differential diagnosis of Parkinson's disease with F-18-FDG and PET. Neurology. 1995;45:1995-2004.
44. Lu L, Zhao C, Liu Y, Sun X, Duan C, Ji M, et al. Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease. Brain Res Brain Res Protoc. 2005;15:46-51.